Cannabinol for Sleep and Insomnia: A Critical Narrative Review and an Olive-Derived Polyphenol Combination Hypothesis

Cannabinol (CBN) is marketed for sleep, but its clinical evidence is limited and heterogeneous. This critical narrative review evaluates CBN-specific sleep studies and considers an olive-derived phenolic combination as a separate, untested clinical hypothesis. Three key randomized trials enrolled different populations and used oral doses of 20–300 mg over one night to four weeks. Primary sleep-quality or sleep-maintenance outcomes were not consistently positive; dose-ranging signals were multiplicity-sensitive and did not identify an optimal dose. At 300 mg, an acute insomnia trial reported selected secondary sleep benefits alongside next-day vigilance and simulated-driving concerns. Rodent findings implicate CBN and its metabolites, but route, exposure, tolerance and dependence limit extrapolation. Oleocanthal studies measured behavioral sleep in disease-model mice, whereas a human olive-phenol trial reported a fatigue benefit rather than a separately demonstrated sleep-domain effect. Parent phenolic instability, metabolism and uncertain target-site exposure weaken direct translation of micromolar assays. The proposed combination warrants exposure-informed investigation, not therapeutic endorsement. Progress requires product-specific safety and analytical qualification, component-controlled experiments and patient-prioritized outcomes alongside established insomnia care.